Alexion Pharmaceuticals, Inc Earning Date (ALXN)

USA |NASDAQ |USD

ALXN Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Feb 2, 2022 Dec 2021 - $3.52 $2.96
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Feb 2, 2022 Dec 2021 - $1.64B $1.59B

Alexion Pharmaceuticals, Inc's next earnings date is Wednesday, Feb 2, 2022 for the fiscal quarter ending Dec 2021.

ALXN Earnings Date & History Chart

ALXN Earnings & Revenue Forecast

ALXN Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 13 $13.49 $12.72 $15.17
Dec 2022 16 $14.33 $12.98 $17.50

ALXN Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 1 / - $13.49 $13.49 $12.86
Dec 2022 1 / - $14.21 $14.25 $14.05

ALXN Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 13 $6.71B $6.31B $7.15B
Dec 2022 15 $7.22B $6.57B $8.04B

ALXN Earnings Date & Revenue History

ALXN Earnings History

|
Show More
Show More

ALXN Revenue History

|
Show More
Show More

Alexion Pharmaceuticals, Inc Next Earnings Date & Report

ALXN Next Earnings Date & Report Preview: Dec 2021 (FQ)

ALXN's next earnings date is Wednesday, Feb 2, 2022 for the fiscal quarter ending Dec 31, 2021.

Alexion Pharmaceuticals, Inc Previous Earnings Dates & Reports

ALXN Previous Earnings Date & Report Recap: Mar 2021 (FQ)

Alexion Pharmaceuticals, Inc's previous earnings date was Apr 30, 2021 for its fiscal quarter ended Mar 31, 2021.

ALXN's earnings per share (EPS) was $3.52, beating the consensus analysts forecast of $3.14 by 12.04%.

The EPS was higher than the previous fiscal quarter (Dec 2020) by 18.92%, and higher than the same period a year before (Mar 2020) by 9.32%.

Revenues were $1.64B, better than the forecast of $1.58B by 3.36%, up by 2.81% from the previous quarter , and up by 13.27% from the same period last year.

The company reported a net income of $636.00M, 18.70% higher than the previous quarter, and higher by 14.06% than the same period a year before.

Free cash flow for the quarter was $507.40M , compared to $763.00M last quarter and $537.40M a year before.

ALXN ended the quarter with $2.53B in total debt, a decrease of -1.17% compared to the previous quarter, and an increase of 2.51% compared to the same quarter a year before.

ALXN Previous Earnings Date & Report Recap: Dec 2020 (FY)

Alexion Pharmaceuticals, Inc's previous annual earnings date was Feb 4, 2021 for its fiscal year ended Dec 31, 2020.

ALXN's earnings per share (EPS) was $12.53, beating the consensus analysts forecast of $12.12 by 3.38% , and higher than the previous year's EPS (Dec 2019) by 18.99%.

Revenues were $6.07B, better than the forecast of $5.99B by 1.36%, and up by 21.61% from previous year's revenue.

The company reported a net income of $603.40M, -74.90% lower than the previous year.

Alexion Pharmaceuticals, Inc reported a free cash flow of $2.90B for its fiscal year, compared to $1.91B a year ago.

The company ended the fiscal year with $2.56B in total debt, an increase of 2.41% compared to the previous year.